Pfizer Advances PF-07328948 Kidney Function Study, Supporting Long-Term Pipeline Value
Pfizer Inc (PFE) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pfizer Inc. (PFE) is running a Phase 1 study called “A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL-COHORT STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF PF-07328948 IN ADULTS WITH RENAL IMPAIRMENT AND HEALTHY ADULT PARTICIPANTS WITH NORMAL RENAL FUNCTION.” The goal is to see how the drug moves through the body and how safe it is in adults with normal and reduced kidney function.
The study tests one oral drug, PF-07328948, given as a single tablet on Day 1. It is designed to check how the medicine is processed and tolerated so that future dosing can be adjusted in people with kidney problems if the program advances.
The trial is interventional and early stage, with groups based on kidney function rather than random assignment. It is open label, meaning everyone knows what they are getting, and the main purpose is to build basic knowledge on drug handling in the body rather than to test clinical benefit.
The study includes adults aged 18 to 80 with normal, moderate, or severe renal function who stay in a clinical unit for about six days. Total follow up lasts up to 64 days, covering screening, the inpatient stay, and safety checks after discharge.
The trial is listed as recruiting, with first submission on 2025-12-18 and the most recent update on 2026-02-28. Key future dates such as primary completion and final completion are not yet posted, but the current status signals that enrollment and data collection are still under way.
For investors, this update is incremental but positive for PFE as it shows continued investment in early pipeline assets and careful work on dosing in high-risk patients. While a small Phase 1 renal study will not move the stock on its own, steady progress across such programs supports sentiment that Pfizer is rebuilding its post-COVID portfolio, in line with industry peers focusing on more targeted, specialty drugs.
The study is currently ongoing and updated, with further details available on the ClinicalTrials portal.
To learn more about PFE’s potential, visit the Pfizer Inc drug pipeline page.
